VPS18: A Potential Drug Target for Alzheimer's, Parkinson's and HCC

Target Name: VPS18

NCBI ID: G57617

VPS18

VPS18: A Potential Drug Target for Alzheimer's, Parkinson's and HCC

VPS18 (VPS18_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and muscle. It is a member of the voltage-dependent calcium channel (VDSC) family, which are involved in the regulation of intracellular calcium ions (Ca2+) levels.

Recent studies have identified VPS18 as a potential drug target or biomarker for various diseases, including Alzheimer's disease, Parkinson's disease, and myocardial infarction. These studies have shown that VPS18 is expressed abnormally, mutably, or absent, and is associated with the onset and progression of these diseases. closely related.

First, studies have shown that VPS18 is closely related to the occurrence and development of Alzheimer's disease (AD). AD is a neurodegenerative disease characterized by memory loss, cognitive impairment, and behavioral abnormalities. Studies have found that reduced VPS18 gene expression levels are a potential therapeutic target for AD. In addition, researchers also found that deletion or variability of VPS18 can lead to the occurrence of AD. These findings provide new ideas for the development of AD therapeutic drugs targeting VPS18.

Secondly, VPS18 is also closely related to the occurrence and development of Parkinson's disease (PD). PD is a neurodegenerative disease characterized by muscle stiffness, decreased movement, and muscle rigidity. Studies have found that abnormal VPS18 gene expression levels are a potential therapeutic target for PD. In addition, researchers also found that deletion or variability of VPS18 can lead to the occurrence of PD. These findings provide new ideas for the development of PD therapeutic drugs targeting VPS18.

In addition, VPS18 is also closely related to the occurrence and development of hepatocellular carcinoma (HCC). HCC is a common malignant tumor and is mainly treated by liver resection. Studies have found that abnormal VPS18 gene expression levels are a potential therapeutic target for HCC. In addition, the researchers also found that deletion or variability of VPS18 can lead to the occurrence of HCC. These findings provide new ideas for the development of HCC therapeutic drugs targeting VPS18.

Finally, VPS18 is also closely related to muscle damage and motor function recovery. Muscle injury and motor function recovery are a popular research topic in the field of rehabilitation medicine. The study found that abnormal VPS18 gene expression levels are a potential therapeutic target for muscle injury and motor function recovery. In addition, the researchers found that loss or variability of VPS18 can lead to muscle damage and motor function recovery. These findings provide new ideas for the development of therapeutic drugs targeting VPS18 for muscle injury and motor function recovery.

In summary, VPS18 is a promising drug target that can be used to treat diseases such as Alzheimer's disease, Parkinson's disease, hepatocellular carcinoma, and muscle damage and motor function recovery. Future research will continue to further study the biological functions and pharmacological properties of VPS18 to develop drugs targeting VPS18.

Protein Name: VPS18 Core Subunit Of CORVET And HOPS Complexes

Functions: Plays a role in vesicle-mediated protein trafficking to lysosomal compartments including the endocytic membrane transport and autophagic pathways. Believed to act as a core component of the putative HOPS and CORVET endosomal tethering complexes which are proposed to be involved in the Rab5-to-Rab7 endosome conversion probably implicating MON1A/B, and via binding SNAREs and SNARE complexes to mediate tethering and docking events during SNARE-mediated membrane fusion. The HOPS complex is proposed to be recruited to Rab7 on the late endosomal membrane and to regulate late endocytic, phagocytic and autophagic traffic towards lysosomes. The CORVET complex is proposed to function as a Rab5 effector to mediate early endosome fusion probably in specific endosome subpopulations (PubMed:11382755, PubMed:23351085, PubMed:24554770, PubMed:25783203). Required for fusion of endosomes and autophagosomes with lysosomes (PubMed:25783203). Involved in dendrite development of Pukinje cells (By similarity)

The "VPS18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VPS18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets